Humana Inc. to Post Fiscal 2022 Earnings of $24.68 Per Share, Jefferies Financial Group Forecasts (NYSE:HUM)
Humana Inc. (NYSE:HUM – Get Rating) – Equity researchers at Jefferies Financial Group raised their fiscal year 2022 earnings estimates for Humana shares in a research report released Wednesday, April 27. Jefferies Financial Group analyst D. Windley now expects the insurance provider to earn $24.68 per share for the year, up from its previous estimate of $24.32. Jefferies Financial Group also released estimates for Humana’s fiscal 2023 earnings at $27.80 EPS.
Several other stock analysts also weighed in on the company. Zacks Investment Research upgraded Humana from a “sell” rating to a “hold” rating and set a target price of $445.00 on the stock in a report on Friday, February 4. SVB Leerink lowered its price target on Humana from $528.00 to $525.00 and set an “outperform” rating on the stock in a Thursday, Feb. 3 research note. StockNews.com upgraded Humana from a “buy” rating to a “strong buy” rating in a Wednesday, April 20 research note. Truist Financial raised its price target on Humana from $460.00 to $490.00 in a Thursday, April 7 research note. Finally, Deutsche Bank Aktiengesellschaft raised its price target on Humana from $418.00 to $435.00 in a Thursday, February 3 research note. Seven research analysts gave the stock a hold rating, twelve gave the company a buy rating and one gave the company a high buy rating. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $486.28.
NYSE HUM opened at $444.56 on Monday. Humana has a fifty-two week low of $351.20 and a fifty-two week high of $475.44. The stock’s 50-day moving average is $440.69 and its two-hundred-day moving average is $435.26. The company has a debt ratio of 0.74, a current ratio of 1.53 and a quick ratio of 1.62. The company has a market capitalization of $56.34 billion, a P/E ratio of 18.86, a price-to-earnings growth ratio of 1.37 and a beta of 0.94. Humana (NYSE:HUM – Get Rating) last released its results on Wednesday, April 27. The insurance provider reported earnings per share of $8.04 for the quarter, beating Thomson Reuters consensus estimate of $6.79 by $1.25. Humana had a return on equity of 17.27% and a net margin of 3.51%. The company posted revenue of $23.97 billion for the quarter, versus analyst estimates of $23.54 billion. During the same period last year, the company earned earnings per share of $7.67. The company’s revenues increased by 16.0% compared to the same quarter last year.
The company also recently announced a quarterly dividend, which will be paid on Friday, July 29. Shareholders of record on Thursday, June 30 will receive a dividend of $0.7875 per share. This represents an annualized dividend of $3.15 and a dividend yield of 0.71%. The ex-dividend date is Wednesday, June 29. Humana’s payout rate is 13.36%.
Institutional investors have recently changed their stake in the company. Spire Wealth Management bought a new equity stake in Humana in Q4 worth $30,000. Bell Investment Advisors Inc acquired a new position in Humana in Q3 worth $26,000. BerganKDV Wealth Management LLC increased its stake in Humana by 885.7% in the 4th quarter. BerganKDV Wealth Management LLC now owns 69 shares of the insurance provider worth $32,000 after purchasing an additional 62 shares during the period. Riverview Trust Co acquired a new position in Humana in Q1 worth $32,000. Finally, Selective Wealth Management Inc. acquired a new position in Humana in Q4 worth $35,000. Institutional investors hold 92.96% of the company’s shares.
Humana Company Profile (Get an assessment)
Humana Inc, together with its subsidiaries, operates as a health and wellness company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental insurance plans to individuals. It also has a contract with the Centers for Medicare and Medicaid Services to administer the Transitional Prescription Drug Plan program for new eligibles with limited income; and contracts with various states to provide Medicaid, dual eligibility, and long-term support services.
This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Humana right now?
Before you consider Humana, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Humana wasn’t on the list.
While Humana currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here